Avalo Therapeutics (AVTX) to Release Earnings on Friday

Avalo Therapeutics (NASDAQ:AVTX) is expected to issue its quarterly earnings data before the market opens on Friday, April 4th. Analysts expect the company to announce earnings of $0.58 per share for the quarter.

Avalo Therapeutics Stock Up 4.4 %

NASDAQ:AVTX opened at $8.73 on Friday. Avalo Therapeutics has a 1 year low of $5.99 and a 1 year high of $34.46. The stock’s 50 day simple moving average is $7.59 and its two-hundred day simple moving average is $9.13.

Analyst Ratings Changes

AVTX has been the subject of several research reports. HC Wainwright reiterated a “neutral” rating on shares of Avalo Therapeutics in a research report on Thursday, March 20th. Jefferies Financial Group started coverage on Avalo Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $23.00 price objective for the company. Piper Sandler started coverage on Avalo Therapeutics in a research report on Friday, February 28th. They issued an “overweight” rating and a $48.00 price target for the company. Wedbush reiterated an “outperform” rating and set a $18.00 price objective on shares of Avalo Therapeutics in a research report on Thursday, March 20th. Finally, Stifel Nicolaus started coverage on Avalo Therapeutics in a report on Tuesday. They issued a “buy” rating and a $36.00 price target on the stock. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $33.00.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.